Sentences with phrase «further uncertainties involved»

Once this criterion for climate change has been met (and I contend that, at best, it has only barely done so), then we can begin to talk about the further uncertainties involved in attribution.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

With the socioeconomical fallout from Brexit still causing uncertainty, plus announcements entailing a complete overhaul of how the industry is regulated and a number of food safety scandals involving big players like 2 Sisters Food Group — 2017 so far has been tumultuous to say the least.

From the examples chosen a pattern emerges that requires a period of sober reflection by any minister or civil servant involved in the planning of major technological projects, for far from the comfort of scientific truth underpinning their decisions, the reality is that the degree of uncertainty involved would appear to reduce the process to a sophisticated form of gambling, with awesome consequences awaiting a wrong decision.

This means that (1) animals are directly involved in an oxygen - regulating cycle or feedback loop that has previously been overlooked, and (2) we can directly test the idea (despite the uncertainties associated with looking so far back in time) by looking for a decrease in ocean oxygenation in conjunction with the spread of bioturbation.

The authors are to be complimented on further detailing the uncertainties involved.

Thus I find the NIPCC review reports of further scientific literature to be stimulating to explore all the uncertainties involved, not just the «consensus» models.

As I see it from my analyses the questions remaining to be asked about the temperature instrumental record involve how well we capture and understand the uncertainty involved in adjusting temperatures, and further knowing the limitations of those methods currently being used.

Lee breaks new ground (as far as I know, anyways) regarding the ethics of decision making under deep uncertainty, with some profound conclusions regarding mitigation versus adaptation: «I assume here that the greater the speculation and uncertainties involved, the weaker the ethical claim.